Abstract: The invention relates to substituted 9-alkyladenines of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined as set forth in the specification. The invention is also directed to the use of such compounds to inhibit adenosine A1 receptor activation in a mammal. The compounds of the present invention are useful as diuretics, renal protectives against acute or chronic renal failure, as well as agents to improve the therapeutic outcome resulting from defibrillation or cardiopulmonary resuscitation by preventing post-resuscitation bradycardia, bradyarrythmia and cardioplegia, to restore cardiac function following a cardioplegic procedure, and to treat or prevent intermittent claudication.

Abstract: The present invention relates to a process for preparing optically active and racemic nitrogen-substituted 2-aminotetralins of the following Formula (I): wherein R1, R2, R3, R4, and n are set in the specification, wherein the process comprises alkylating the corresponding unsubstituted 2-aminotetralin of Formula (II): with a reactant of the Formula (III): Z—(CH2)n—R3  (III) wherein Z is a leaving group, in the presence of a base, wherein the base is selected from the group consisting of alkali metal carbonate and alkali metal bicarbonate, and wherein the amount of the base is less than about a 1.9-fold molar excess with respect to the amount of the 2-aminotetralin.